Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,066 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators. Shiota M, et al. Among authors: fujimoto k. Cancer Immunol Immunother. 2023 Jun;72(6):1903-1915. doi: 10.1007/s00262-023-03367-w. Epub 2023 Feb 2. Cancer Immunol Immunother. 2023. PMID: 36729213 Free PMC article.
Risk factors for ipsilateral adrenal involvement in renal cell carcinoma.
Ito K, Nakazawa H, Marumo K, Ozono S, Igarashi T, Shinohara N, Fukuda M, Tsushima T, Naito S, Hayakawa M; Japanese Society of Renal Cancer. Ito K, et al. Urology. 2008 Aug;72(2):354-8. doi: 10.1016/j.urology.2008.02.035. Epub 2008 May 12. Urology. 2008. PMID: 18468657
Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A randomized, double-blind, multicentre phase II/III study.
Inoue K, Anai S, Fujimoto K, Hirao Y, Furuse H, Kai F, Ozono S, Hara T, Matsuyama H, Oyama M, Ueno M, Fukuhara H, Narukawa M, Shuin T. Inoue K, et al. Among authors: fujimoto k. Photodiagnosis Photodyn Ther. 2015 Jun;12(2):193-200. doi: 10.1016/j.pdpdt.2015.03.008. Epub 2015 Apr 2. Photodiagnosis Photodyn Ther. 2015. PMID: 25843912 Clinical Trial.
Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study.
Miyake M, Tatsumi Y, Fujimoto K, Nagao K, Sakano S, Matsuyama H, Inamoto T, Azuma H, Yasumoto H, Shiina H; Nishinipon Uro-Oncology Collaborative Group. Miyake M, et al. Among authors: fujimoto k. Jpn J Clin Oncol. 2016 Dec;46(12):1148-1155. doi: 10.1093/jjco/hyw128. Epub 2016 Aug 30. Jpn J Clin Oncol. 2016. PMID: 27576438
A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, Fujimoto K, Kawanishi H, Sato F, Narita S, Satoh T, Saito H, Sugimoto M, Teishima J, Masumori N, Egawa S, Sakai H, Okada Y, Terachi T, Ogawa O; ZAPCA Study Group. Kamba T, et al. Among authors: fujimoto k. Int J Clin Oncol. 2017 Feb;22(1):166-173. doi: 10.1007/s10147-016-1037-2. Epub 2016 Sep 10. Int J Clin Oncol. 2017. PMID: 27614621 Clinical Trial.
Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial.
Oyama M, Sugiyama T, Nozawa M, Fujimoto K, Kishida T, Kimura G, Tokuda N, Hinotsu S, Shimozuma K, Akaza H, Ozono S. Oyama M, et al. Among authors: fujimoto k. Jpn J Clin Oncol. 2017 Jun 1;47(6):551-559. doi: 10.1093/jjco/hyw194. Jpn J Clin Oncol. 2017. PMID: 28334974 Free PMC article. Clinical Trial.
4,066 results